Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JAGX OTCMKTS:OMGAQ NASDAQ:REVB NYSEAMERICAN:TOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Animal Health$2.10-5.4%$2.82$1.93▼$35.25$4.26M0.4399,053 shs39,859 shsOMGAQOmega Therapeutics$0.00+150.0%$0.09$0.00▼$1.69$40K0.57306,853 shs97,423 shsREVBRevelation Biosciences$2.55+2.0%$2.58$2.11▼$168.00$3.84M-0.06231,077 shs55,696 shsTOVXTheriva Biologics$0.39-0.1%$0.46$0.38▼$7.15$3.54M0.77371,612 shs125,741 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Animal Health-5.41%+2.94%-19.54%-75.32%-92.15%OMGAQOmega Therapeutics+150.00%-90.24%-98.40%-98.40%-99.87%REVBRevelation Biosciences+2.00%+2.41%+1.59%-73.27%-94.99%TOVXTheriva Biologics-0.08%-12.60%-15.95%-26.40%-92.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAGXJaguar Animal Health1.8227 of 5 stars3.53.00.00.01.10.00.6OMGAQOmega Therapeutics2.3706 of 5 stars3.33.00.00.00.61.71.3REVBRevelation Biosciences0.3885 of 5 stars0.02.00.00.01.40.01.3TOVXTheriva Biologics1.3409 of 5 stars3.03.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAGXJaguar Animal Health 3.00Buy$60.002,757.14% UpsideOMGAQOmega Therapeutics 2.67Moderate Buy$8.00399,900.00% UpsideREVBRevelation Biosciences 0.00N/AN/AN/ATOVXTheriva Biologics 2.00Hold$6.001,438.46% UpsideCurrent Analyst Ratings BreakdownLatest OMGAQ, TOVX, JAGX, and REVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/8/2025TOVXTheriva BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAGXJaguar Animal Health$11.69M0.34N/AN/A$12.29 per share0.17OMGAQOmega Therapeutics$3.09M0.04N/AN/A$1.05 per share0.00REVBRevelation BiosciencesN/AN/AN/AN/A$27.05 per shareN/ATOVXTheriva BiologicsN/AN/AN/AN/A$6.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)OMGAQOmega Therapeutics-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/AREVBRevelation Biosciences-$15.04M-$307.86N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)TOVXTheriva Biologics-$25.65M-$33.06N/A∞N/AN/A-97.50%-55.31%N/ALatest OMGAQ, TOVX, JAGX, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025JAGXJaguar Animal Health-$7.13N/AN/AN/A$3.27 millionN/A8/8/2025N/AREVBRevelation Biosciences-$4.46N/AN/AN/AN/AN/A5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million5/8/2025Q1 2025REVBRevelation Biosciences-$20.64-$6.33+$14.31-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAGXJaguar Animal HealthN/AN/AN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ATOVXTheriva BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAGXJaguar Animal Health22.201.080.70OMGAQOmega TherapeuticsN/AN/AN/AREVBRevelation BiosciencesN/A3.603.60TOVXTheriva Biologics0.101.531.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAGXJaguar Animal Health12.04%OMGAQOmega Therapeutics97.47%REVBRevelation Biosciences12.80%TOVXTheriva Biologics6.17%Insider OwnershipCompanyInsider OwnershipJAGXJaguar Animal Health4.55%OMGAQOmega Therapeutics8.50%REVBRevelation Biosciences2.30%TOVXTheriva Biologics1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJAGXJaguar Animal Health501.91 million1.83 millionNo DataOMGAQOmega Therapeutics12055.37 million50.66 millionOptionableREVBRevelation Biosciences101.53 million1.50 millionNot OptionableTOVXTheriva Biologics209.06 million8.93 millionNot OptionableOMGAQ, TOVX, JAGX, and REVB HeadlinesRecent News About These CompaniesTheriva Biologics Sets 2025 Shareholder Meeting DateJune 25, 2025 | tipranks.comTheriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review ...May 29, 2025 | finanznachrichten.deTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the ...May 29, 2025 | morningstar.comMTheriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | finanznachrichten.deTheriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial ResultsMay 14, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Closing of $7.5 Million Public OfferingMay 9, 2025 | finanznachrichten.deTheriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics DevelopmentMay 9, 2025 | nasdaq.comTheriva Biologics Announces Closing of $7.5 Million Public OfferingMay 8, 2025 | globenewswire.comTheriva Biologics, Inc.: Theriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | finanznachrichten.deTheriva’s oncolytic virus succeeds in pancreatic cancer study, but stock fallsMay 7, 2025 | endpts.comETheriva Biologics Announces Pricing of $7.5 Million Public OfferingMay 7, 2025 | globenewswire.comTheriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 10, 2025 | globenewswire.comTheriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025April 2, 2025 | nasdaq.comTheriva Biologics says IDMC considers VCN-01 to be well toleratedApril 2, 2025 | markets.businessinsider.comTheriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New OrleansMarch 21, 2025 | nasdaq.comTheriva™ Biologics to Present at the 2025 NeauxCancer ConferenceMarch 19, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)March 12, 2025 | markets.businessinsider.comTheriva Biologics Reports 2024 Financial Results and ProgressMarch 7, 2025 | tipranks.comTheriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial ResultsMarch 6, 2025 | globenewswire.comTheriva™ Biologics to Participate in the Q1 Investor Summit VirtualMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOMGAQ, TOVX, JAGX, and REVB Company DescriptionsJaguar Animal Health NASDAQ:JAGX$2.10 -0.12 (-5.41%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.14 +0.04 (+2.14%) As of 08/7/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Omega Therapeutics OTCMKTS:OMGAQ$0.0020 +0.00 (+150.00%) As of 08/7/2025 01:00 PM EasternOmega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Revelation Biosciences NASDAQ:REVB$2.55 +0.05 (+2.00%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.54 -0.01 (-0.39%) As of 08/7/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Theriva Biologics NYSEAMERICAN:TOVX$0.39 0.00 (-0.08%) Closing price 08/7/2025 04:10 PM EasternExtended Trading$0.39 +0.00 (+0.26%) As of 08/7/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
